March 15, 2023
Charlottesville, Virginia

HemoShear Therapeutics Attends Family and Scientific Meetings

Last week, a team from HemoShear attended a family meeting hosted by the Propionic Acidemia Foundation and Lurie Children's Hospital, one of the sites currently participating in the HERO Study.

"The meeting was well-attended and drew families from 10 states, which is quite impressive for a rare disease," HemoShear's vice president of clinical operations, Mavis Waller, shared. "The program featured dieticians, clinicians, and genetic counselors to help guide families through their disease journey and educate them about clinical trial participation."

Later this month, the team will travel to Salt Lake City, Utah, to sponsor and attend the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting, where they will present a poster on HERO baseline disease biomarkers[1] and another on hospitalization trends[2] for MMA and PA patients. During the conference, Dr. Kimberley Chapman of Children's National Hospital, and lead investigator for the HERO Study, will lead a session on small molecule therapies for MMA and PA.

If you plan to attend SIMD, the HemoShear team would love to connect! Please feel free to reach out.

[1] Chapman KA, Gannon JL, Vockely J, Prada CE, Berry S, Waller M, Armstrong AJ, Horn P. Disease-Related Biomarker Levels in Propionic and Methylmalonic Acidemia Patients Enrolled in a Phase 2 Study. 2023.
[2] Armstrong AJ, MacEachern D, Hoang S, Lawson M, Stepanians M, Hayes M, Horn P. Insurance Claims Data Analysis of Hospitalization Frequency and Duration in Propionic and Methylmalonic Acidemia Patients. 2023.

HemoShear's clinical team booth at the GMDI 2022 Annual Meeting
Pictured (left to right): Phuong Nguyen, Clinical Trial Manager; Meaghan Shea, Clinical Administrator; Mavis Waller, Vice President, Clinical Operations; Allison Armstrong, Executive Director, Rare Disease Programs

HemoShear Therapeutics, Inc. discovers novel biological targets and advances drug programs to treat metabolic disorders with significant unmet patient need.